Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
ZVSA Stock Chart & Stats
$0.13
-$0.05(-3.87%)
At close: 4:00 PM EST
$0.13
-$0.05(-3.87%)
Day’s Range― - ―
52-Week Range$0.11 - $1.94
Previous CloseN/A
Volume38.43K
Average Volume (3M)51.59K
Market Cap
$2.10M
Enterprise Value$1.58M
Total Cash (Recent Filing)$527.98K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue60.47
Enterprise Value/Gross Profit120.94
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineZyVersa's concentrated R&D focus on renal and inflammatory indications provides a clear strategic roadmap and concentrated scientific expertise. Over 2-6 months this preserves optionality for clinical readouts, partnerships, or licensing outcomes that can materially advance the business model beyond pre-commercial status.
Low Financial LeverageNear-zero reported debt reduces fixed financial obligations and interest burden, giving management flexibility to prioritize R&D spending or pursue non-debt funding. For a biotech with cash burn, low leverage lowers short-term insolvency risk and widens options for strategic financings or partnerships.
Multiple Modality PlatformsHaving both antibody and small-molecule programs diversifies scientific and commercial risk across modalities. This broader technical platform increases likelihood of at least one development path reaching value-inflection points, and supports multiple partnering or asset-sale strategies over the medium term.
Bears Say
Immaterial Revenue; Heavy LossesTTM revenue near zero combined with very large operating and net losses indicates the company is pre-commercial and unable to internally generate meaningful sales. Over months this constrains reinvestment capacity, forces reliance on external capital, and increases dilution risk for existing shareholders.
Persistent Negative Cash FlowConsistently negative operating and free cash flow reflect cash-burning operations that must be financed externally. This creates ongoing runway and refinancing risk, limits strategic flexibility, and makes the company sensitive to capital markets conditions for ensuring continuity of clinical programs over the next several months.
Negative Equity; Diminished Capital BaseNegative shareholders' equity signals cumulative losses that have eroded the company's capital base, potentially weakening counterparties' confidence and contractual leverage. Structurally, this reduces ability to absorb shocks, complicates financing terms, and limits strategic options such as partnerships or acquisitions.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $1.94 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $2.10M.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 23 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on Nov 19, 2025. The company reported -$2.56 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.56.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$2.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
6.64%
Insiders
<0.01% Other Institutional Investors
93.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---